Email bulletins

Archive

November 2022

  • News from the AASLD Liver Meeting, Washington, DC
  • Only 11 countries on target to eliminate hepatitis C by 2030
  • Simplified tenofovir regimen as effective as recommended preventive treatment in pregnant women with hepatitis B
  • Some people remain at risk for liver cancer after being cured of hepatitis C
  • UK community test-and-treat service achieves high hepatitis C cure rate in people who use drugs
  • Severe acute hepatitis in children still does not have a definitive cause
  • Bepirovirsen treatment leads to sustained loss of hepatitis B markers for up to one in five
  • VIR-2218 combined with monoclonal antibody or pegylated interferon delivers potent suppression of hepatitis B

July 2022

  • News from the 2022 International Liver Congress
  • People cured of hepatitis C remain at higher risk of death due to liver- and drug-related causes
  • WHO publishes updated guidance on hepatitis C infection
  • Bulevirtide leads to sustained improvement for people with hepatitis D
  • Experimental hepatitis B combination suppresses key marker but fails to achieve functional cure
  • Bepirovirsen suppresses hepatitis B surface antigen, moves forward to larger functional cure studies
  • Short-course treatment prevents hepatitis C after organ transplant
  • Re-treatment of hepatitis C is highly effective after the first combination fails
  • Is this your copy of the infohep news bulletin?

May 2022

  • Severe acute hepatitis of unknown cause in children: an update
  • UK emergency department screening for viral hepatitis feasible and acceptable
  • Ukraine: viral hepatitis and harm reduction services for refugees
  • People with diabetes or heavy alcohol consumption at higher risk of severe fibrosis after hepatitis C cure
  • Is this your copy of the infohep news bulletin?

April 2022

  • Severe acute hepatitis of unknown origin in children
  • Sofosbuvir/velpatasvir is suitable for treatment of genotype 4 variants in Africa
  • UK report urges re-think on hepatitis C reinfection
  • High hepatitis C reinfection rate in prison study highlights harm reduction needs
  • Test-and-treat leads to sustained fall in hepatitis C in Swiss gay men with HIV
  • Is this your copy of the infohep news bulletin?

March 2022

  • COVID-19 pandemic led to a 30% drop in new hepatitis C treatments in the United States
  • Accessible care achieves higher hepatitis C cure rate in people who inject drugs
  • Depression, anxiety, cognitive performance improve after hepatitis C cure
  • Hepatitis C prevalence down by 40% since 2015 in England
  • Metabolic disorders cause liver damage in people with HIV more often than viral hepatitis in lower-income countries
  • Fatty liver disease raises the risk of cardiovascular disease in people with HIV
  • Is this your copy of the infohep news bulletin?

February 2022

  • Immunoglobulin-free strategy highly effective for prevention of mother-to-child hepatitis B transmission in Cambodia
  • Universal hepatitis C screening in pregnancy improves case detection
  • Antihistamine use halved the risk of liver cancer in people with viral hepatitis
  • Hepatitis C treatment and cure targets for people living with HIV still not being met in Europe
  • New cases of hepatitis C declining in people with HIV as access to treatment broadens
  • Is this your copy of the infohep news bulletin?

January 2022

  • Some people remain at risk for liver cancer despite hepatitis C treatment
  • Bulevirtide for hepatitis D proves effective in real-world studies
  • Hepatitis B may increase cancer risk in people with HIV
  • One in five new cases of hepatitis C in people who inject drugs due to unstable housing, modelling shows
  • Re-infection with hepatitis C has fallen among people with HIV in Europe
  • Prioritise harm reduction services to prevent hepatitis C re-infection, Scottish study finds
  • Is this your copy of the infohep news bulletin?